[ADRU] BLDRS Europe 100 ADR Index

Overview

Type of security: Fund

Tags: ADRs, Equity, ETF, Europe, Index Based, Not Inversed, Regional, Unleveraged

The data is delayed by 15 minutes.

 

Price: 19.06 Change: -0.06 (-0.31%)
Ext. hours: Change: 0 (0%)

chart ADRU

Refresh chart

Strongest Trends Summary For ADRU

ADRU is in the medium-term up 12% in 6 months. In the long-term down -17% below S&P in 2 years and down -54% below S&P in 17 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to provide investment results that correspond generally, before fees and expenses, to the price and yield performance of the Bank of New York Europe 100 ADR Index. The fund typically invests substantially all of its assets in the securities that make up the index. It is non-diversified.

Technical Data
High 52 week24.56 Low 52 week18.24 Last close21.38 Last change-0.19%
RSI82.69 Average true range0.07 Beta0.92 Volume200
Simple moving average 20 days0.61% Simple moving average 50 days2.49% Simple moving average 200 days0.77%
Performance Data
Performance Week-0.23% Performance Month0.52% Performance Quart9.38% Performance Half-4%
Performance Year-11.32% Performance Year-to-date13.7% Volatility daily0.53% Volatility weekly1.2%
Volatility monthly2.45% Volatility yearly8.49% Relative Volume22.35% Average Volume872.4
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings
Price to Book Value Price to Earnings Total expense ratio Total net assets
Weighted market capitalization

News

2018-10-29 14:50:02 | Recommendations for GlaxoSmithKline on October 29

2018-10-24 07:30:37 | What Analysts Recommend for Novartis after Q3 Earnings

2018-10-22 15:50:02 | How Novartis’s Innovative Medicines Business Performed in Q3

2018-10-10 09:01:06 | A Closer Look at Novartis’s Innovative Medicines Segment

2018-10-04 09:01:57 | Novartis ADR’s Performance and Revenue Estimates for Q3 2018

2018-10-01 09:02:58 | How GlaxoSmithKline’s Segments Performed

2018-09-06 14:21:11 | Novartis to Divest Portions of Sandoz US to Aurobindo

2018-08-29 09:00:53 | Novartis’s Sandoz in Q2 2018

2018-08-24 08:12:17 | Novartis’s SOLAR-1 Trial Met Primary Endpoint

2018-08-14 09:01:09 | What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

2018-07-24 10:32:26 | Novartis’s Key Developments in July

2018-06-04 09:01:11 | A Short Guide to the Novartis-AveXis Deal

2018-05-16 10:31:34 | Analysts’ Recommendations for AstraZeneca as of May 15

2018-04-30 10:31:33 | GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business

2018-04-18 07:32:25 | Novartis’s 1Q18 Estimates: Expectations for Sandoz

2018-04-09 16:30:14 | Assessing the Performance of Novartis Stock in 1Q18

2018-03-15 07:32:05 | How Novartis’s Alcon Performed in 4Q17

2018-03-13 10:30:37 | How AstraZeneca’s Other Products Portfolio Performed in 4Q17

2018-03-02 09:03:05 | Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17

2018-02-09 09:00:27 | How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy

2018-02-02 15:35:02 | Novartis’s 4Q17 Earnings: Segment-Wise Revenues

2018-02-02 09:00:29 | Shingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline

2018-01-22 08:25:10 | Inside Novartis’s 4Q17 Earnings: Analyst Estimates

2018-01-12 09:45:42 | Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

2017-09-18 14:19:43 | How Is Novartis’s Lucentis Positioned after 1H17?

2017-09-14 10:37:30 | How TEVA’s Respiratory Franchise Is Positioned after 1H17

2017-09-04 10:37:48 | AstraZeneca’s Segment-Wise Performance in 2Q17

2017-09-01 10:37:13 | GlaxoSmithKline’s Vaccines Business in 2Q17

2017-08-31 10:37:25 | Understanding Novartis’s Recent Developments after 2Q17

2017-08-18 07:37:45 | Performance of Sanofi’s Established Products in 2Q17

2017-08-01 10:39:44 | GlaxoSmithKline’s 2Q17 Earnings: HIV Business

2017-07-18 09:08:13 | Novartis’s 2Q17 Estimates: Alcon, the Eye Care Business

2017-03-28 09:06:15 | A Look at Novartis’s Financial Guidance and Priorities for 2017

2017-02-21 14:47:07 | 3 Reasons Why These European ETFs Compelling Bets Now

2017-02-03 07:36:23 | Novartis’s Financial Guidance and Priorities for 2017

ADRU motifs

Equity
Europe